

Predictive Control of the Blood Glucose Level in Type I Diabetic Patient Using Delay Differential Equation Wang Model

Abstract

Because of increasing risk of diabetes, the measurement along with control of blood sugar has been of great importance in recent decades. In type I diabetes, because of the lack of insulin secretion, the cells cannot absorb glucose leading to low level of glucose. To control blood glucose (BG), the insulin must be injected to the body. This paper proposes a method for BG level regulation in type I diabetes. The control strategy is based on nonlinear model predictive control. The aim of the proposed controller optimized with genetics algorithms is to measure BG level each time and predict it for the next time interval. This merit causes a less amount of control effort, which is the rate of insulin delivered to the patient body. Consequently, this method can decrease the risk of hypoglycemia, a lethal phenomenon in regulating BG level in diabetes caused by a low BG level. Two delay differential equation models, namely Wang model and Enhanced Wang model, are applied as controller model and plant, respectively. The simulation results exhibit an acceptable performance of the proposed controller in meal disturbance rejection and robustness against parameter changes. As a result, if the nutrition of the person decreases instantly, the hypoglycemia will not happen. Furthermore, comparing this method with other works, it was shown that the new method outperforms previous studies.

Keywords: Algorithms, blood glucose, diabetes mellitus type I, glucose, humans, hypoglycemia, insulin, meals, nonlinear dynamics

Introduction

Diabetes is one of the most common endocrine diseases in which insulin secretion is not enough to regulate blood glucose (BG) due to destruction of pancreatic β cells. On the other hand, in case of high BG, glucagon secretion also stops, and thus, BG level exceeds the normal range of 80–140 mg/dl.^[1]

The most important goal in the treatment of diabetes is to maintain BG in the normal range. In fact, as depicted in Figure 1, the main objective is to find the optimal control signal for insulin injection rate. According to block diagram in Figure 1, the rate of insulin injections is applied by the pump in diabetic patients as a control signal.

Some efforts to capture the glucose–insulin mechanism have led to the formulation of various glucose insulin kinetic models. So far, several models have been suggested to predict the dynamic behavior of glucose–insulin system.^[2–5]

Negative feedback ordinary differential equation (ODE) model of Sturis and Tolic (2000) and delay differential equation (DDE) models of Engelborghs (2001), Bennett and Gourley (2004), and Kuang, Li and Mason (2006), together with the Wang and Li (2007) and the extended Wang (2009) models are among the current and valid ones based on ODE and DDE.^[2,3,6–9]

Primitive models for diabetes could not model time delay from the moment BG level increases till insulin secretion time. In some models to get insulin secretion fluctuations, insulin is divided into two components of plasma and intracellular – this considered a disadvantage for the proposed model. However, in this study, the delayed nonlinear model of Wang and Li is used considering the nonlinear behavior of insulin–glucose interaction for type I diabetic patient.

Closed loop control methods to regulate BG in type I diabetic patients are mainly based on the model and also the experimental data.

Mojgan Esna-Ashari,
Maryam Zekri^{1,2},
Masood Askari³,
Noushin Khalili⁴

Department of Medical Physics and Medical Engineering, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, ¹Electrical and Computer Engineering, Isfahan University of Technology, Isfahan, Iran, ²Medical Image and Signal Processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, ³IUT Branch, Culture and Research, Academic Centre for Education, Isfahan, Iran, ⁴Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Esna-Ashari M, Zekri M, Askari M, Khalili N. Predictive control of the blood glucose level in type I diabetic patient using delay differential equation Wang model. *J Med Sign Sence* 2017;7:8-20.

Address for correspondence:
Dr. Maryam Zekri, Electrical and Computer Engineering, Isfahan University of Technology, Isfahan 84156-83111, Iran.
E-mail: mzekri@cc.iut.ac.ir

Website: www.jmss.mui.ac.ir




Figure 1: Closed loop controller for a diabetic individual^[12]

Methods based on the experimental data identify model parameters using glucose–insulin data and results are then obtained by applying proportional–integral–derivative (PID) controllers.^[10] In addition, various control methods including H_∞,^[11,12] adaptive,^[13] proportional–derivative (PD),^[14] PID,^[15] fuzzy,^[16,17] etc. have been proposed to regulate BG levels in type I diabetic patients. These methods differ in terms of employing control strategies, use of constraints, mathematical models, and ease of implementation, each with its own advantages and disadvantages.

In 2008, Gianni Marchetti proposed an improved PID control strategy for BG control and critically evaluated *in silico* using a physiologic model of Hovorka.^[18] An artificial pancreas strategy using constrained model predictive control is developed to achieve closed-loop glucose control for type I diabetes in 2009. A system of meal detection and meal size estimation is also developed to automatically administer meal insulin boluses as feed-forward action to unmeasured meals.^[19] In 2010, a model-based predictive control scheme was applied to a newly developed diabetic patient model. The controller was provided with a feed-forward loop to improve meal compensation, a gain-scheduling scheme to account for different BG levels, and an asymmetric cost function to reduce hypoglycemic risk.^[20] In 2011, a system based on a nonlinear model-predictive controller was developed which used a personalized glucose–insulin metabolism model, consisting of two compartmental models and a recurrent neural network. The model took as input the patient's information regarding meal intake, glucose measurements, and insulin infusion rates, and provided glucose predictions.^[21] A novel automatic adaptive control strategy based on frequent glucose measurements and a self-tuning control technique was validated based on a simulation study for 200 virtual patients in 2013. The adaptive control strategy was shown to be highly effective in controlling BG concentration.^[22] Control methods based on nonlinear models have been introduced which employ physiological behavior of patients to provide different control methods in regulating BG. It is obvious that if the model behavior is more similar to the patient's body, the resulting control law is more accurate too. Hence, providing a suitable approach to control delayed nonlinear models for diabetic patients is of great importance.

In this study, the proposed control system is capable of predicting BG levels and injecting insulin so that the BG level always lies within normal range, showing suitable

performance against meal disturbances and uncertainties in the model.

Delay Differential Equation Model

These models range from simple expressions relating glucose and insulin, to very complicated mathematical models. To simulate the glucose dynamics of the patient's body, two well-known mathematical models are considered. The first model, proposed by Wang *et al.* in 2007^[2] for glucose–insulin interactions in the body, consists of 2 DDEs describing various sections in the body. They performed both qualitative and quantitative studies of the dynamics of the model. The analytical results showed the existence and uniqueness of a stable periodic solution corresponding to ultradian insulin secretion oscillations. Numerical simulation results of insulin administration based on their model matched with the findings of the clinical studies.

The second model, known as the Enhanced Wang model,^[3] consists of 2 DDEs too. The Enhanced Wang model is a nonlinear compartmental model for insulin therapy for both type I and type II diabetes mellitus, in which the insulin degradation rate assumes Michaelis–Menten kinetics.

It is well known that Michaelis–Menten kinetics is suitable for the response function in chemical reaction, when the reaction rate does not increase indefinitely when an excess of resource is available.

However, the existing models for insulin therapies take it for granted that the response function of insulin clearance is proportional to the insulin concentration. Their analysis shows that it is possible to simulate pancreatic insulin secretion by exogenous insulin infusions, and their numerical simulations provide clinical strategies for insulin–administration practices.

The Wang and the Enhanced Wang models have similar dynamical behaviors.

Equations related to Wang and Enhanced Wang models are shown in (1) and (2), respectively:

$$\begin{aligned} \frac{dG}{dt} &= G_{in} - f_2(G(t)) - f_3(G(t))f_4(I(t - T_3)) \\ &\quad + f_5(I(t - T_2)) \\ \frac{dI}{dt} &= I_{in}(t) - d_i I(t) \end{aligned} \quad (1)$$

$$\begin{aligned} \frac{dG}{dt} &= G_{in} - f_2(G(t)) - f_3(G(t))f_4(I(t)) + f_5(I(t)) \\ \frac{dI}{dt} &= \alpha I_{in} + \beta f_1(G(t - T_1)) - \frac{d_1(I(t))}{d_2 + I(t)} \end{aligned} \quad (2)$$

$\alpha > 0, \beta \in [0, 1]$, for type I diabetes: $\beta = 0$. (no insulin is secreted from the pancreas)

Here, the uptake of food glucose, modeled by (3),^[2] is denoted by G_{in} :

$$G_{in}(t) : \begin{cases} 0.05 + \frac{5}{15}t & 0 \leq t < 15(\text{min}) \\ 0.05 + 5\frac{45-t}{45-15} & 15 \leq t < 45(\text{min}) \\ 0.05 & 45 \leq t \leq 240(\text{min}) \end{cases} \quad (3)$$

In these models, $G(t)$ is the output and G_{in} and $I_{in}(t)$ are the system inputs. Insulin reduction in body differs from person to person. In Wang model, insulin reduction is defined as d_i and for Enhanced Wang model with Michaelis–Menten kinetics:

$$\frac{d_1(I(t))}{d_2 + I(t)}$$

where d_1 is the maximum insulin clearance rate, and d_2 is the half-saturation value.

Functions of the models are as follows:

$$\begin{aligned} f_1(G) &= R_m / (1 + \exp((C_1 - G/V_g)/a_1)) \\ f_2(G) &= U_b / (1 - \exp(-G/(C_2 V_g))) \\ f_3(G) &= G / (C_3 V_g) \\ f_4(I) &= U_0 + (U_m - U_0) / (1 + \exp(-\beta \ln(I/C_4 + 1/(E t_i)))) \\ f_5(I) &= R_g / (1 + \exp(\alpha(I/V_p - C_5))) \end{aligned} \quad (4)$$

$f_1(G)$: Glucose-dependent insulin secretion.

$f_2(G)$: Insulin-independent glucose consumption by the brain and nerve cells.

$f_3(G)f_4(I)$: Glucose-dependent insulin consumption by muscle cells and fat.

$f_5(I)$: Glucose production controlled by insulin concentration.

Parameters related to functions f_2 to f_5 are mentioned in Table 1.

Designing Nonlinear Predictive Controller for Insulin Injection System

The method presented in this study is based on predictive nonlinear controller optimized with genetic algorithm.

Figure 2 depicts the basic principle of model predictive control. On the basis of the measurements obtained at time t , the controller forecasts the future.^[23] Dynamic manner of the system over a prediction horizon T_p determines the input such that a predetermined performance objective function is optimized. If there were no model-plant

Parameters	Units	Values
V_g	1	10
U_b	mg/min	72
C_2	mg/l	144
C_3	mg/min	1000
V_p	1	3
V_i	1	11
t_i	min	100
R_m	mU/min	210
C_1	mg/l	2000
a_1	mg/l	300
U_0	mg/min	40
U_m	mg/min	940
β	1	1.77
C_4	mU/l	80
R_g	mg/min	180
α	l/mU	0.29
C_5	mU/l	26
E	l/min	0.2
V_a	1	10




Figure 2: Principle of model predictive control^[18]

discrepancy, and if the optimization problem were solvable for infinite horizons, then the input function at time $t = 0$ to the system is applicable for all times $t \geq 0$. The resulting manipulated input function will be implemented only until the next measurement is available. The time gap between recalculations can vary; however, it is supposed to be fixed – the measurement will occur every δ sampling time-units. Using the new measurement at time $t + \delta$, the entire process-prediction and optimization will be repeated to find a new input function with the control and prediction horizons moving forward. As shown in Figure 2, the input u is denoted as an arbitrary function of

time. The calculation of the applied input based on the predicted system behavior allows the inclusion of constraints on states and inputs as well as the optimization of a given cost function. The stabilization problem for a class of systems is introduced by the following nonlinear set of differential (5):

$$X(T) = F(X(T), U(T), X(0)) = X_0 \quad (5)$$

which is subject to input and state constraints of the form:^[23]

$$\begin{aligned} u(t) &\in U, & t \geq 0 \\ x(t) &\in X, & t \geq 0 \end{aligned} \quad (6)$$

where $x(t)$ and $u(t)$ represent the states and inputs vector, respectively. U and X constraints are given in (7), where u_{\min} , u_{\max} and x_{\min} , x_{\max} are constant vectors:^[23]

$$\begin{aligned} u &\{u \in R^m \mid u_{\min} \leq u \leq u_{\max}\} \\ x &\{x \in R^n \mid x_{\min} \leq x \leq x_{\max}\} \end{aligned} \quad (7)$$

To distinguish between the real system and the system model used to predict the future within the controller, the internal variables in the controller are denoted by a bar (e.g., \bar{x}, \bar{u}). The finite horizon optimal control problem commonly described above is mathematically formulated as following:^[23]

$$\min J(x(t), u(t); T_c, T_p) \quad (8)$$

$$J(x(t), u; T_c, T_p) = \int_i^{i+T_p} F(x(\tau), u(\tau)) d\tau \quad (9)$$

The function F , hereinafter called cost function, specifies the favorable control performance that can arise. The standard quadratic form is the simplest and most often the used one:

$$\begin{aligned} F(x, u) &= (x - x_d)^T Q (x - x_d) \\ &+ (u - u_d)^T R (u - u_d) \end{aligned} \quad (10)$$

where u_d and x_d are the desired input and output, respectively. Q and R are symmetric, definite positive, and weighing matrices. T_p is the horizon of the predicted output, and T_c is the control horizon. Eq. (10) gives the error between desired output and model-predicted output. To obtain the output values in the next time interval, the optimal input values in time period T_c are used, and then, the value of the control variable is set constant in the last calculated value.^[23]

The block diagram of nonlinear model predictive control optimized with genetic algorithm is given in Figure 3, composed of a system model and plant.

The controller is designed based on the data provided by the Wang model. To show the effectiveness and robustness of the designed controller, it is used to regulate BG predicted by both Wang and the Enhanced Wang models.

To design predictive controller for the model, an objective function needs to be designed. Real-time optimization of objective function will lead to design of a control signal that is able to track the suitable reference path by predicting system behavior. According to the studies, the optimal amount of BG is 110 mg/dl; nevertheless, the 80-to-140 interval is also known as green or healthy zone. Therefore, this objective function is proposed:




Figure 3: Block diagram of nonlinear model predictive control optimized with genetic algorithm

$$J = \left\{ \begin{aligned} &\| \sum_{j=1}^N \hat{G}(t+j) - G_S \|^2 Q_1(j) + \\ &\| \sum_{j=1}^N \hat{G}(t+j) - G_{up} \|^2 Q_2(j) + \\ &\| \sum_{j=1}^N \hat{G}(t+j) - G_{down} \|^2 Q_3(j) + \\ &\sum_{j=1}^M \| W(Z^{-1})u(t+j-1) \|^2 R(j) \end{aligned} \right\} \quad (11)$$

In (11), \hat{G} is the anticipated blood sugar, G_S is the optimal blood sugar level (110), G_{up} and G_{down} are high (140) and low (80) blood sugar values, respectively, t is present, $u(t+j)$ is future control signal, $W(Z^{-1})$ is defined to solve a single problem of dynamic matrix that is equal to $1-Z^{-1}$, N is the prediction horizon, and M is the control horizon. Most importantly, $Q_{1,2,3}$ values have to be regulated so that blood sugar levels do not lie in unhealthy conditions.

As a result, parameter tuning is as follows:

$$\begin{aligned} Q_1 &= 1 \\ Q_2 &= \begin{cases} 0 & \text{if } \hat{G} < G_{up} \\ 1000 & \text{if } \hat{G} > G_{up} \end{cases} \\ Q_3 &= \begin{cases} 1000 & \text{if } \hat{G} < G_{down} \\ 0 & \text{if } \hat{G} > G_{down} \end{cases} \end{aligned} \quad (12)$$

The R -value in (11), denoting objective function penalty for taking too much insulin, is taken as 100 in simulations. The prediction horizon is set as 45 min.^[11]

As the objective function is optimized with genetic algorithm for genetic algorithm parameters, maximum number of repetitions is 30, initial population size is 25, crossover value is 50%, and mutation rate is considered as 40%. In addition, the *Rollet Wheel Selection* is considered as the method for selecting members of recombination.

Simulations and Results

In this section, the simulation results in the absence of controller (open loop system) are examined, the need to use the controller is checked, and the results of adding controller to the system are discussed. The proposed controller is then tested against disturbances and uncertainties in the system and the obtained results will be finally compared with other studies, all presented in Tables 2 and 3.

The proposed simulation method was implemented in MATLAB software.

Open loop response system

Figure 4 depicts the amount of sugar entering the body in standard conditions. The profile provided in this diagram is a standard one defined based on (3).

In the absence of insulin injection, blood sugar is 142 mg/dl and insulin level is 18U. Please note that the initial system was deliberately put in unhealthy conditions. Results are presented in Figure 5. As seen, blood sugar level always remains in unhealthy situation. In this figure, the amount of injected insulin is zero, but in Figure 6, we set the rate of injection at a nonzero level. Because of lack of a feedback loop in injection system, the amount of BG




Figure 4: Glucose intake rate (G_{in}) in (3)

Table 2: Numerical simulation results

Simulation terms	Daily infused insulin (mU/kg)	Blood glucose \pm SD (mg/dl)	Time consuming (s)
Normal	674.6	109.4 \pm 7.3	11.6
Disturbance I	680.4	109.0 \pm 3.7	12.0
Disturbance II	686.2	109.6 \pm 7.6	11.8
d_i (1 + 20%)	734.1	110.8 \pm 5.5	11.9
d_i (1 - 20%)	537.2	109.5 \pm 5.6	11.9
τ_3 increasing	605.1	108.9 \pm 9.2	11.6
τ_2 increasing	708.8	109.7 \pm 7.2	11.5
Uncertainty in model	676.3	116.7 \pm 3.1	11.6
Uncertainty in model with disturbances	683.6	117.2 \pm 3.7	11.7

is decreased until it becomes as low as dangerous situation.

Closed loop response system

As depicted in Figure 7, the amount of BG level is immediately shifted from unauthorized to authorized level when the controller is used.

Disturbances and uncertainties in the system

To evaluate the system performance in food disturbances mode, two states of impact noise and increasing blood sugar input were studied. In the first case, the patient is assumed to consume sugar at a time other than the time period defined in sugar intake profile. This process exhibits some changes during the time period 8–12 [Figure 8]. As seen, the controller has an appropriate performance in this case and does not permit above-limit deviation. However, an excessive amount of 1.6% insulin is injected here to compensate for the imposed disturbances.

In this study, another disturbance was studied in which one of the peaks of sugar intake by patient experienced a 20-fold jump [Figure 9]. In this case, to use the controller, an increase of 1.8% in insulin injection is implemented every 45 min.

Insulin reduction parameter varies for different people in *Wang* model. Therefore, to compare results for various modes, d_i received 20% increase and also 20% reduction. Results are depicted in Figures 10 and 11. In more critical situations involving d_i increase, insulin injection increases by 8–10%. However, in d_i decline mode, injected insulin drops by 20% as shown in Table 2.

Another parameter that may vary in different patients is time delay of insulin-dependent glucose consumption




Figure 5: Open loop response system. The rate of insulin (*I*) and glucose (*G*) change in 24 h




Figure 6: Open loop response system with constant injection rate. The rate of insulin (*I*) and glucose (*G*) change in 24 h




Figure 7: Closed loop response system. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 8: System behavior for impact noise mode. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 9: System behavior while imposing noise in one of the peaks of sugar intake. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 10: System behavior in parametric uncertainty for d_i increase mode ($d_i(1 + 20\%)$). Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 11: System behavior in parametric uncertainty for d_1 reduction mode ($d_1(1-20\%)$). Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 12: System behavior with delay time of 50 instead of 15 min. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h

τ_2 and also time delay related to insulin-dependent glucose secretion τ_3 . Any time delay of more than 15 min for glucose secretion caused by insulin incline will put the patient at risk for a severe drop in blood sugar. Figure 12 represents system simulation in the event that time delay is 50 min (according to Wang *et al.*^[21]).

As seen in above chart, although some drop in blood sugar occurs, the controller is still able to return BG level to permissible range by 10% less insulin infusion. Result of increasing time delay for glucose consumption from 5 to 30 min is shown in Figure 13.

Another case studied in this research is the incompatibility between the model used in controller structure for prediction and the real model of glucose in the patient. To do so, the Wang model was used in controller structure, and the incremental Wang model, as an extension to Wang model and suitable for both diabetes types 1 and 2, was used in system structure. In this model, insulin consumption rate is considered more realistically as a function of insulin level in blood. The results of this study verify the appropriate performance of our system even in the absence of agreement between controller structure model and system dynamics model. Simulation results are seen in Figure 14.

Now, we examine the case in which model uncertainty and the noise resulting from impact and increased glucose consumption occur simultaneously. As shown in Figure 15, despite the fact that BG level violates the allowable range in noisy moments, the controller can well bring it back to the range within permissible limit.

Comparison of the results

On the basis of Table 3, our proposed controller outperforms in regulating BG levels and also reducing daily insulin dosage compared with other controllers such as fuzzy PD, fuzzy proportional–integral (PI), genetics optimal fuzzy PI, and genetics optimal fuzzy

Table 3: Comparison of the daily infused insulin under the genetics optimal nonlinear model-predictive controller (proposed approach) and that of Lee and Bequette^[19]

Controller	Daily infused insulin (mU/kg)
Fuzzy PD	7232.4
Fuzzy PI	1087.1
Genetics optimal fuzzy PI	708.8
Genetics optimal fuzzy PID	708.1
Genetics optimal NMPC	674.6




Figure 13: System behavior with delay time of 30 instead of 5 min. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h




Figure 14: Evaluating model uncertainty and the mismatch between controller structure model and system model. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h

PID that were proposed in Al-Fandi *et al.*^[24] with same glucose–insulin model. Fortunately, Ref.^[24] is one of the previous studies in this area that reports the amount of insulin injection per day. In other references, like,^[1,23,25,26] the main goal is only to protect the BG at safe level. We can refer to inattention to optimization of insulin injection per day as the main drawback of latest studies. In this research, we optimize the amount of injection in addition to maintaining the glucose at the safe level using a nonlinear model predictive control system.

Conclusions

As evident, this study was aimed at providing a predictive control method for improving the performance of a system for automatic injection of insulin to diabetic patients. In this regard, after observing the unstable response of open-loop system (untimely insulin injection), the proposed method was implemented. In

this approach, the dynamic model of blood sugar and insulin variations is seen within the structure of the controller, and the controller can predict variations of blood sugar and insulin level using current measurements.

Following the prediction done by the controller, the optimum insulin injection is computed on a real-time basis using genetic algorithm so that the unhealthy blood sugar in a patient is maintained in its lowest possible value in 24h. To evaluate the performance of the designed controller, various scenarios ranging from normal and noisy conditions with unpredicted factors, to parametric uncertainty, and finally model uncertainty were designed and implemented. The results showed the ability of the controller system to regulate blood sugar levels, ensuring the accuracy of its performance in different conditions. The results of this research can well compete with works done by other researchers.




Figure 15: Evaluation of model uncertainty along with noise. Glucose intake rate (G_{in}), insulin injection (I_{in}), blood glucose level (G), and blood insulin level (I) in 24 h

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini Federici M, *et al.* Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. *Physiol Meas* 2004;25:905-20.
- Wang H, Li J, Kuang Y. Mathematical modeling and qualitative analysis of insulin therapies. *Math Biosci* 2007;210:17-33.
- Wang H, Li J, Kuang Y. Enhanced modelling of the glucose-insulin system and its applications in insulin therapies. *J Biol Dyn* 2009;3:22-38.
- Wu Z, Chui CK, Hong GS, Khoo E, Chang S. Glucose-insulin regulation model with subcutaneous insulin injection and evaluation using diabetic inpatients data. *Comput Methods Programs Biomed* 2013;111:347-56.
- Sorensen JT. A physiologic model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes. [Doctoral Dissertation]. Massachusetts Institute of Technology; 1985.
- Toli IM, Mosekilde E, Sturis J. Modeling the insulin-glucose feedback system: The significance of pulsatile insulin secretion. *J Theor Biol* 2000;207:361-75.
- Engelborghs K, Lemaire V, Bélair J, Roose D. Numerical bifurcation analysis of delay differential equations arising from physiological modeling. *J Math Biol* 2001;42:361-85.
- Bennett DL, Gourley SA. Asymptotic properties of a delay differential equation model for the interaction of glucose with plasma and interstitial insulin. *Appl Math Comput* 2004;151:189-207.
- Li J, Kuang Y, Mason CC. Modeling the glucose-insulin regulatory system and ultradian insulin secretory oscillations with two explicit time delays. *J Theor Biol* 2006;242: 722-35.
- Marchetti G, Barolo M, Jovanovic L, Zisser H, Seborg DE. An improved PID switching control strategy for type 1 diabetes. *IEEE Trans Biomed Eng* 2008;55:857-65.

11. Femat R, Ruiz-Velázquez E, Quiroz G. Weighting restriction for intravenous insulin delivery on T1DM patient via control. *IEEE Trans Autom Sci Eng* 2009;6:239-47.
12. Kienitz KH, Yoneyama T. A robust controller for insulin pumps based on H-infinity theory. *IEEE Trans Biomed Eng* 1993;40:1133-7.
13. Goh W, Pasquier M, Quek C. Adaptive control of infusion pump for Type-I diabetes control using a self-tuning regulator. 10th International Conference on Control, Automation, Robotics and Vision, 2008. ICARCV 2008, IEEE. December 17, 2008 p. 1379-84.
14. Chase JG, Wake GC, Lam ZH, Lee JY, Hwang KS, Shaw G. Steady-state optimal insulin infusion for hyperglycemic ICU patients. 7th International Conference on Control, Automation, Robotics and Vision, 2002. ICARCV 2002, vol. 3. IEEE. December 02, 2002, p. 1168-73.
15. Li C, Hu R. Simulation study on blood glucose control in diabetics. The 1st International Conference on Bioinformatics and Biomedical Engineering, 2007. ICBBE 2007, IEEE. July 06, 2007, p. 1103-6.
16. Ibbini MS, Masadeh MA. A fuzzy logic based closed-loop control system for blood glucose level regulation in diabetics. *J Med Eng Technol* 2005;29:64-9.
17. Yasini S, Naghibi-Sistani MB, Karimpour A. Active insulin infusion using fuzzy-based closed-loop control. 3rd International Conference on Intelligent System and Knowledge Engineering, 2008. ISKE 2008, vol. 1. IEEE. November 17, 2008, p. 429-34.
18. Marchetti G, Barolo M, Jovanovi L, Zisser H, Seborg DE. A feedforward-feedback glucose control strategy for type I diabetes mellitus. *J Process Control* 2008;18:149-62.
19. Lee H, Bequette BW. A closed-loop artificial pancreas based on model predictive control: Human-friendly identification and automatic meal disturbance rejection. *Biomed Signal Process Control* 2009;4:347-54.
20. Abu-Rmileh A, Garcia-Gabin W. A gain-scheduling model predictive controller for blood glucose control in type I diabetes. *IEEE Trans Biomed Eng* 2010;57:2478-84.
21. Zarkogianni K, Vazeou A, Mougiakakou SG, Proutzou A, Nikita KS. An insulin infusion advisory system based on autotuning nonlinear model-predictive control. *IEEE Trans Biomed Eng* 2011;58:2467-77.
22. Ottavian M, Barolo M, Zisser H, Dassau E, Seborg DE. Adaptive blood glucose control for intensive care applications. *Comput Methods Programs Biomed* 2013;109:144-56.
23. Findeisen R, Allgöwer F. An introduction to nonlinear model predictive control. 21st Benelux Meeting on Systems and Control, vol. 11. March 19, 2002 p. 119-41.
24. Al-Fandi M, Jaradat MA, Sardahi Y. Optimal PID-fuzzy logic controller for type I diabetic patients. 2012 8th International Symposium on Mechatronics and its Applications (ISMA). IEEE. April 10, 2012 p. 1-7.
25. Toffanin C, Messori M, Di Palma F, De Nicolao G, Cobelli C, Magni L. Artificial pancreas: Model predictive control design from clinical experience. *J Diabetes Sci Technol* 2013;7:1470-83.
26. Hovorka R, Kremen J, Blaha J, Matias M, Anderlova K, Bosanska L, *et al.* Blood glucose control by a model predictive control algorithm with variable sampling rate versus a routine glucose management protocol in cardiac surgery patients: A randomized controlled trial. *J Clin Endocrinol Metab* 2007;92:2960-4.